Citations

Clear

219 citation(s) found for "Do, Ron".

National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards
Hachinski, Vladimir , Iadecola, Costantino , Petersen, Ron, Breteler, Monique M.B. , Nyenhuis, David L. , Black, Sandra E. , DeCarli, Charles , Merino, José G. , Kalaria, Raj N. , Vinters, Harry V. , Wallin, Anders, Dichgans, Martin , Marler, John R., Leblanc, Gabrielle G., DeCarli, Charles , Powers, William J. , Holtzman, David M. , Rosenberg, Gary A. , Dichgans, Martin

Mayo Clinic

Stroke | August 17, 2006 | Volume: 37 | Issue: 9 | Pages: 2220-2241

10.1161/01.str.0000237236.88823.47 | PMID 16917086 Get It

Background and Purpose— One in 3 individuals will experience a stroke, dementia or both. Moreover, twice as many individuals will have cognitive impairment short of dementia as either stroke or dementia. The commonly used stroke scales do not measure cognition, while dementia criteria focus on the late stages of cognitive impairment, and are heavily biased toward the diagnosis of Alzheimer disease. No commonly agreed standards exist for identifying and describing individuals with cognitive impairment, particularly in the early stages, and especially with cognitive impairment related to vascular factors, or vascular cognitive impairment. Methods— The National Institute for Neurological Disorders and Stroke (NINDS) and the Canadian Stroke Network (CSN) convened researchers in clinical diagnosis, epidemiology, neuropsychology, brain imaging, neuropathology, experimental models, biomarkers, genetics, and clinical trials to recommend minimum, common, clinical and research standards for the description and study of vascular cognitive impairment. Results— The results of these discussions are reported herein. Conclusions— The development of common standards represents a first step in a process of use, validation and refinement. Using the same standards will help identify individuals in the early stages of cognitive impairment, will make studies comparable, and by integrating knowledge, will accelerate the pace of progress.
IC–P–007: fMRI activation patterns during encoding and recognition in normal elderly and amnestic mild cognitive impairment patients
Ivnik, Robert J., Petersen, Ron, Jack, Clifford R. , Machulda, Mary M. , Senjem, Matthew L. , Smith, Glenn E. , Boeve, Bradley F. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_21 | Pages: No page available

10.1016/j.jalz.2006.05.2212 Get It

P1–308: Association of variants in Aβ processing genes with late onset Alzheimer's disease (LOAD)
Younkin, Linda H., Lok, Johann, Zou, Fanggeng, Carrasquillo, Minerva M. , Budjak, Ron, Younkin, Samuel , Petersen, Ronald C. , Graff‐Radford, Neill R. , Younkin, Steven G., Dincman, Toros A. , Raam, Manu S. , Carrasquillo, Minerva M. , Ma, Li

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_7 | Pages: No page available

10.1016/j.jalz.2006.05.686 Get It

P1–224: Population–based prevalence of mild cognitive impairment
Roberts, Rosebud O., Rocca, Walter A. , Cha, Ruth, Ivnik, Robert J., Petersen, Ron, Boeve, Bradley F. , Geda, Yonas E.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_6 | Pages: No page available

10.1016/j.jalz.2006.05.601 Get It

Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome
Fox, Keith A.A. , Mehta, Shamir R. , Peters, Ron J.G. , Zhao, Feng , Lakkis, Nasser , Yusuf, Salim , Gersh, Bernard J. , Yusuf, Salim

Mayo Clinic

Circulation | August 16, 2004 | Volume: 110 | Issue: 10 | Pages: 1202-1208

10.1161/01.cir.0000140675.85342.1b | PMID 15313956 Get It

Background— Antiplatelet therapy and antithrombin therapy have been demonstrated to reduce the risk of cardiac events in patients presenting with acute coronary syndrome, yet all effective therapies also increase the risk of bleeding. Methods and Results— In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial, 12 562 patients were randomized to clopidogrel or placebo in addition to aspirin, and the primary outcome was cardiovascular (CV) death, myocardial infarction (MI), or stroke. The benefits were consistent among those undergoing percutaneous coronary intervention (PCI) [9.6% for clopidogrel, 13.2% for placebo; relative risk (RR), 0.72; 95% CI, 0.57 to 0.90], coronary artery bypass grafting (CABG) surgery (14.5% for clopidogrel 16.2% for placebo; RR, 0.89; 95% CI, 0.71 to 1.11), and medical therapy only (8.1% for clopidogrel, 10.0% for placebo; RR, 0.80; 95% CI, 0.69 to 0.92; test for interaction among strata, 0.53). For CABG during the initial hospitalization (530 for placebo, 485 for clopidogrel), the frequency of CV death, MI or stroke before CABG was 4.7% for placebo and 2.9% for clopidogrel (RR, 0.56; 95% CI, 0.29 to 1.08). For the entire study, there was a 1% excess of major bleeding but no significant excess of life-threatening bleeding. Among patients undergoing CABG, the rates of life-threatening bleeding were 5.6% for clopidogrel and 4.2% for placebo (RR, 1.30; 95% CI, 0.91 to 1.95; both nonsignificant). Conclusions— The benefits versus risks of early and long-term clopidogrel therapy (freedom from CV death, MI, stroke, or life-threatening bleeding) are similar in those undergoing revascularization (CABG or PCI) and in the study population as a whole. Overall, the benefits of starting clopidogrel on admission appear to outweigh the risks, even among those who proceed to CABG during the initial hospitalization.
Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes
Peters, Ron J.G. , Mehta, Shamir R. , Fox, Keith A.A. , Zhao, Feng , Kopecky, Steven L., Díaz, Rafael , Commerford, Patrick, Valentín, Vicent, Yusuf, Salim , Lewis, Basil S. , Yusuf, Salim

Mayo Clinic

Circulation | September 22, 2003 | Volume: 108 | Issue: 14 | Pages: 1682-1687

10.1161/01.cir.0000091201.39590.cb | PMID 14504182 Get It

Background— We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS). Methods and Results— In the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial, 12 562 patients with ACS using aspirin, 75 to 325 mg daily, were randomized to clopidogrel or placebo for up to 1 year. In this analysis, patients were divided into the following 3 aspirin dose groups: ≤100 mg, 101 through 199 mg, and ≥200 mg. The combined incidence of cardiovascular death, myocardial infarction, or stroke was reduced by clopidogrel regardless of aspirin dose, as follows: ≤100 mg, 10.5% versus 8.6% (relative risk [RR], 0.81 [95% CI, 0.68 to 0.97]); 101 to 199 mg, 9.8% versus 9.5% (RR, 0.97 [95% CI 0.77 to 1.22]); and ≥200 mg, 13.6% versus 9.8% (RR, 0.71 [95% CI, 0.59 to 0.85]). The incidence of major bleeding increased with increasing aspirin dose both in the placebo group (1.9%, 2.8%, and 3.7%, respectively; P =0.0001) and the clopidogrel group (3.0%, 3.4%, and 4.9%, respectively; P =0.0009); thus, the excess risk with clopidogrel was 1.1%, 1.2%, and 1.2%, respectively. The adjusted hazard ratio for major bleeding for the highest versus the lowest dose of aspirin was 1.9 (95% CI 1.29 to 2.72) in the placebo group, 1.6 (95% CI 1.19 to 2.23) in the clopidogrel group, and 1.7 (95% CI 1.36 to 2.20) in the combined group. Conclusions— In patients with ACS, adding clopidogrel to aspirin is beneficial regardless of aspirin dose. Bleeding risks increase with increasing aspirin dose, with or without clopidogrel, without any increase in efficacy. Our findings suggest that the optimal daily dose of aspirin may be between 75 and 100 mg, with or without clopidogrel.
The Workforce in Otolaryngology‐Head and Neck Surgery: Moving into the Next Millennium
Pillsbury, Harold C., Cannon, C. Ron, Holzer, Susan E. Sedory, Jacoby, Itzhak, Benninger, Michael S. , Denneny, James C. , Cheng, Eme Y., Hagner, Alison P., Meyer, Gregg S. , Nielsen, David R. , Smith, Richard V.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | February 4, 2003 | Volume: 123 | Issue: 3 | Pages: 341-356

10.1067/mhn.2000.109761 | PMID 10964321 Get It

OBJECTIVEThe goal was to examine the current scope of otolaryngologists’ practices, their geographic distribution, and the roles otolaryngologists and other specialists play in caring for patients with otolaryngic and related conditions of the head and neck.STUDY DESIGNA large national survey and administrative claims databases were examined to develop practice profiles and compile a physician supply for otolaryngology. A focus group of otolaryngologists provided information to model future scenarios.RESULTSThe current and predicted workforce supply and demographics are at a satisfactory level and are decreasing as a proportion of the increasing population. Empiric data analysis supports the diverse nature of an otolaryngologist's practice and the unique role for otolaryngologists that is not shared by many other providers. Together with the focus group results, the study points to areas for which more background and training are warranted.CONCLUSIONSThis study represents a first step in a process to form coherent workforce recommendations for the field of otolaryngology.
In vitro selection of fibronectin gain-of-function mutations
Tani, P, Loftus, Joseph C. , Bowditch, Ron D.

Mayo Clinic

Biochemical Journal | July 28, 2002 | Volume: 365 | Issue: 1 | Pages: 287-294

10.1042/bj20020067 | PMID 12071856 Get It

Directed protein evolution, which employs a combination of random mutagenesis, phage display, and in vitro selection, was used to identify second-site suppressors of the fibronectin (Fn) cell binding domain mutation Asp1495Ala (RGA). The mutations in the Fn 9th (3fn9) and 10th (3fn10) type III repeats obtained after selection on purified integrins αIIbβ3(D119Y) and α5β1 are reported. The 3fn9–10(D1495A) phage with substitution mutations at Asp1418, which is located within the linker region between 3fn9 and 3fn10, enhanced binding to the integrins αIIbβ3 and α5β1, but not αvβ3. The substitution mutations identified at residue Asp1418 were introduced into the native recombinant 3fn9–10 sequence and found to augment binding to αIIbβ3, demonstrating that the observed gain-of-function phenotype was independent of the multivalent character of the phage. These results support the following conclusions. First, regions of Fn in addition to the RGD loop are in close proximity to αIIbβ3 and α5β1 and are capable of participating in the binding to these integrins. Secondly, the conformational relationship between the 3fn9 and 3fn10 modules may be an important factor in the binding of Fn to these two integrins. Thirdly, other altered properties of Fn-integrin interactions, such as integrin specificity, may also be selected. This is the first description of Fn mutations that augment binding to integrins. The ability to select for particular phenotypes in vitro and the subsequent characterization of these mutations should further our understanding of the molecular details involved in the association of integrins and their ligands. Additionally, these higher-affinity 3fn9–10 ligands provide a starting point for further in vitro evolution and engineering of integrin-specific modules.
Macrophage-dependent Apoptosis of CD4+ T Lymphocytes from HIV-infected Individuals Is Mediated by FasL and Tumor Necrosis Factor
Badley, Andrew D. , Dockrell, David H. , Schut, Ron, Leibson, Paul J., Payá, Carlos V., Simpson, Maggie , Schut, Ronald L., Lynch, David H. , Badley, Andrew D

Mayo Clinic

The Journal of Experimental Medicine | July 26, 2002 | Volume: 185 | Issue: 1 | Pages: 55-64

10.1084/jem.185.1.55 | PMID 8996241 Get It

Apoptosis of bystander uninfected CD4+ T lymphocytes by neighboring HIV-infected cells is observed in cell culture and in lymphoid tissue of HIV-infected individuals. This study addresses whether antigen-presenting cells such as human macrophages mediate apoptosis of CD4+ T cells from HIV-infected individuals. Uninfected human macrophages, and to a larger degree, HIV-infected macrophages mediate apoptosis of T cells from HIV-infected, but not from uninfected control individuals. This macrophage-dependent killing targets CD4+, but not CD8+ T lymphocytes from HIV-infected individuals, and direct contact between macrophages and lymphocytes is required. Additional analyses indicated that the apoptosis-inducing ligands, FasL and tumor necrosis factor (TNF), mediate this macrophage-induced apoptosis of CD4+ T cells. These results support a role for macrophage-associated FasL and TNF in the selective depletion of CD4+ T cells in HIV-infected individuals.